| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis NICE has recommended ivacaftor–tezacaftor–elexacaftor (Kaftrio), within it marketing authorisation, and so it is available on the NHS in Wales as follows:
This recommendation applies only in circumstances where the approved commercial arrangement price is utilised. |
|
Medicine details |
|
| Medicine name | ivacaftor/tezacaftor/elexacaftor (Kaftrio®) |
| Formulation | film-coated tablet; granules |
| Reference number | 4321 |
| Indication | Kaftrio tablets are indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kaftrio granules are indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene |
| Company | Vertex Pharmaceuticals UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/07/2024 |
| NICE guidance | |
| Commercial arrangement | CAA |
| Further information See also: |
|